pharma · Hepatocellular Carcinoma · Hepatocellular Carcinoma (HCC) · TPST
Tempest Therapeutics
Tempest Therapeutics patent portfolio — 10 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Brisbane, USA
- Employees
- 14
- Programs
- 3
- Drugs
- 1
- Patents
- 10
Tempest Therapeutics patents
10 pharmaceutical patents indexed for Tempest Therapeutics. 0 expire within 24 months.
Tempest Therapeutics has 10 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12215093
Bicyclic carboxamides and methods of use thereof
granted -
US 11795156
Bicyclic carboxamides and methods of use thereof
granted -
US 11738009
Bicyclic compounds and their use in the treatment of cancer
granted -
US 11666557
Triazolone compounds and uses thereof
granted -
US 11638704
Bicyclic compounds and their use in the treatment of cancer
granted -
US 11472789
Bicyclic carboxamides and methods of use thereof
granted -
US 11066405
Bicyclic compounds and their use in the treatment of cancer
granted -
US 10968201
Bicyclic carboxamides and methods of use thereof
granted -
US 10568871
Triazolone compounds and uses thereof
granted -
US 9862708
Pyrazolone compounds and uses thereof
granted
Frequently asked questions
How many patents does Tempest Therapeutics have?
10 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Tempest Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.